Skip to main navigation Skip to search Skip to main content

Progressive stent technologies: New approaches for the treatment of cardiovascular diseases

  • Erasmus MC

Research output: Contribution to a Journal (Peer & Non Peer) › Review article › peer-review

11 Citations (Scopus)

Abstract

The CYPHER® (Cordis, Johnson & Johnson) sirolimus-eluting stent and the TAXUS® (Boston Scientific) paclitaxel-eluting stent have been extensively evaluated and have been proven to be significant novel tools for the treatment of coronary artery disease. Several sirolimus derivatives have already emerged, receiving CE Mark approval. However, in the future, it is likely that drugs presently under investigation will address additional mechanisms associated with neointimal formation, either as single agents or in combination with antiproliferative compounds. Concurrently, alterations on stent platform design (helicoidal, open-closed cell), coatings (biodegradable, bioabsorbable, nanoporous) and polymers are being explored.

Original languageEnglish
Pages (from-to)783-797
Number of pages15
JournalExpert Opinion on Drug Delivery
Volume3
Issue number6
DOIs
Publication statusPublished - Nov 2006
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Bioabsorbable stent
  • Drug-eluting stent
  • Polymer coating
  • Stent design

Fingerprint

Dive into the research topics of 'Progressive stent technologies: New approaches for the treatment of cardiovascular diseases'. Together they form a unique fingerprint.

Cite this